No Data
Optimistic Investors Push Sanbo Hospital Management Group Limited (SZSE:301293) Shares Up 36% But Growth Is Lacking
Sanbo Neurology: Report for the third quarter of 2024
San Bona Neuroscience (301293.SZ): net income of 0.105 billion yuan in the first three quarters, a year-on-year increase of 42.93%.
Gelonghui October 25th | Sanbo Brain Science (301293.SZ) released the third quarter report of 2024, achieving revenue of 1.059 billion yuan in the first three quarters, a year-on-year increase of 9.83%; net income attributable to shareholders of listed companies was 0.105 billion yuan, a year-on-year increase of 42.93%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 89.2952 million yuan, a year-on-year increase of 18.28%; basic earnings per share was 0.51 yuan.
Sanbo Hospital Management Group Limited's (SZSE:301293) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Sanbo Brain (301293.SZ): intends to acquire 70% equity of Da Hang Guangze in the form of capital increase and equity transfer.
On September 27, Gelonhui announced that it plans to use its own funds, over-raised funds, and interest generated from raised funds totaling 0.42 billion yuan to increase the capital of its wholly-owned subsidiary Sanbo (Chongqing) Property Management Co., Ltd. (referred to as "Chongqing Sanbo"), which will then invest in Sichuan Daxing Guangze Medical Investment Management Co., Ltd. (referred to as "Daxing Guangze" or the "target company"). The investment this time is intended to acquire 70% of the equity of Daxing Guangze through capital increase and equity transfer. The target company holds 100% equity of Chengdu Dongli Hospital, which operates as a tertiary comprehensive hospital.
Some Shareholders Feeling Restless Over Sanbo Hospital Management Group Limited's (SZSE:301293) P/E Ratio
Revenues Not Telling The Story For Sanbo Hospital Management Group Limited (SZSE:301293) After Shares Rise 27%No Data
No Data
